In conclusion, although NLRP3 activation can induce hepatic inflammation and fibrosis, inhibiting the NLRP3 pathway does not ameliorate any of the histological features of NASH in an experimental mouse model suggesting that they are not mediated by NLRP3 inflammation. Here, NLRP3 is linked to metabolic dysfunction-associated steatohepatitis.